New Strategies for Treatment of Inflammatory Bowel Disease by Ole Haagen Nielsen
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDICINE
REVIEW ARTICLE
published: 24 March 2014
doi: 10.3389/fmed.2014.00003
New strategies for treatment of inflammatory bowel
disease
Ole Haagen Nielsen*
Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
Edited by:
Giovanni Cammarota, School of
Medicine and Surgery, Catholic
University, Italy
Reviewed by:
Ludovico Abenavoli, University
Magna Graecia, Italy
Alejandro Piscoya, Universidad
Peruana de Ciencias Aplicadas, Peru
*Correspondence:
Ole Haagen Nielsen, Department of
Gastroenterology D112M, Herlev
Hospital, University of Copenhagen,
75 Herlev Ringvej, Herlev,
Copenhagen DK-2730, Denmark
e-mail: ohn@dadlnet.dk
The etiology of inflammatory bowel disease (IBD), of which ulcerative colitis (UC) and
Crohn’s disease (CD) are the two most prevailing entities, is unknown. However, IBD is
characterized by an imbalanced synthesis of pro-inflammatory mediators of the inflamed
intestine, and for more than a decade tumor necrosis factor-(TNF) α has been a major target
for monoclonal antibody therapy. However, TNF inhibitors are not useful for one third of all
patients (i.e. “primary failures”), and further one third lose effect over time (“secondary
failures”). Therefore, other strategies have in later years been developed including mono-
clonal antibodies targeting the interleukin (IL)-6 family of receptors (the p40 subunit of
IL-12/IL-23) as well as monoclonal antibodies inhibiting adhesion molecules (the α4β7 hete-
rodimers), which direct leukocytes to the intestinal mucosa. Recently, small molecules,
which are inhibitors of Janus kinases (JAKs), hold promise with a tolerable safety profile
and efficacy in UC, and the field of nanomedicine is emerging with siRNAs loaded into
polyactide nanoparticles that may silence gene transcripts at sites of intestinal inflamma-
tion. Thus, drug development for IBD holds great promise, and patients as well as their
treating physicians can be hopeful for the future.
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Inflammatory bowel disease (IBD), of which ulcerative colitis
(UC) and Crohn’s disease (CD) are the two prevailing entities, con-
stitutes an important global public health problem with increasing
incidence (1). The disease is multifactorial driven mainly by an
inappropriate immune response to gut microbes in a genetically
predisposed host (2). IBD occurs worldwide but its incidence
and prevalence vary widely among geographic regions (1). The
increased prevalence will as a consequence translate into higher
health care expenditures, and patient costs for IBD, which are
higher than for asthma, hypertension, and chronic obstructive
pulmonary disease (3), will become increasingly relevant to the
economy as a whole (4). Additionally, recent mortality data have
revealed an increase in intermediate and long-term mortality
among patients with IBD with even higher percentages for patients
diagnosed as children or adolescents (5).
Conventional management of IBD follow a step-up strategy
(6, 7), and for several years the treatment options were glucocorti-
coids, immunomodulators [i.e. thiopurines and methotrexate (the
latter for CD only)], cyclosporine, 5-aminosalicylic acid (for UC
only), and antibiotics (8, 9), but in later years there has been a
landmark of discoveries and advancements in our understanding
of the innate and adaptive immune responses. These discoveries
have been paralleled by an exponential increase in the number of
new and investigational therapeutic targets briefly mentioned in
the following (10).
TNF INHIBITORS
For one and a half decade, the treatment of more than 1.3 mil-
lion patients with tumor necrosis factor (TNF-α) inhibitors have
generated huge amounts of safety and long-term efficacy data.
This class include monoclonal antibodies of which infliximab was
first on the market, followed by adalimumab, certolizumab pegol
(a Fab′ fragment), and recently golimumab (Table 1) (11). One
of the drawbacks attributed to biologics is, however, the loss of
response caused by antibody formation and the costs associated
with long-term therapy (12). Notably, around 33% fail to respond
to TNF inhibitors and another third of all patients lose response
over time and need to be switched to another TNF inhibitor
(11). Nevertheless, prospective randomized controlled trials have
demonstrated that combination therapy with thiopurines and
infliximab is superior to either agent alone in both UC and CD (13,
14). Thus, combination therapy reduces anti-infliximab antibod-
ies and approximately doubles the level of infliximab in circulation
(13, 15). Altogether, these data suggest that concomitant therapy
leads to optimized clinical outcomes and that the use of com-
bination therapy in IBD is likely to increase (16). Nevertheless,
it should be noticed that the underlying modes of action of the
available TNF inhibitors are rather complex (17).
There is an apparent shift in cost profile from surgery and
hospitalization toward TNF inhibitor treatment, but the relatively
consistent overall total costs suggest that the high cost of these bio-
logics are partly compensated for by the reduction in surgery and
hospitalization rates (18–20). Whether long-term TNF inhibitor
therapy is cost effective in IBD has yet to be determined, at least
from the society’s perspective. Even with early introduction to a
TNF inhibitor, one in five patients with UC (21) and seven of 10
patients with CD (22) will eventually require colectomy or small
bowel resections. However, careful monitoring of changes in the
cost of care in IBD will ensure that timely economic decisions can
be made.
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Table 1 | Novel drugs for treatment of inflammatory bowel disease.
Structure Drug Route of administration Indications Target(s)
Infliximab (75% human, 25% mouse) Intravenous CD and UC TNF-α
Adalimumab (100% human) Subcutaneous injection CD and UC TNF-α
Golimumab (100% human) Subcutaneous injection UC TNF-α
Certolizumab pegol (humanized Fab fragment) Subcutaneous injection CD TNF-α
Ustekinumab (100% human) Subcutaneous injection CD IL-12 and IL-23
Natalizumab (humanized) Intravenous CD α4β1 and α4β7
Vedolizumab (humanized) Intravenous CD and UC α4β7
Tofacitinib (small molecule) Oral UC JAK1 and JAK3
siRNA (nanomolecule) Oral CD and UC siRNA targeting
TNF-α transcripts
CD, Crohn’s disease; UC, ulcerative colitis; TNF, tumor necrosis factor; IL, interleukin; JAK, Janus kinase; siRNA, small interfering RNA.
The double-stranded structure is degraded to single strands, and the red part is bound to target mRNA and directs it for cleavage).
The structure of antibodies, small molecule or siRNA is shown (the human antibody part of TNF inhibitors is in green color).
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Regarding the combination therapy with thiopurines and TNF
inhibitors, some but not all studies show an association between
this combination and adverse events, particularly non-Hodgkin
lymphoma, other cancers, and opportunistic infections (23, 24).
More information is needed to conclude which patients bene-
fit from combination therapy and what is the optimal duration
of treatment (11). Further, controversy exists regarding which
patients with IBD require early aggressive treatment versus those
who can be treated with the more conventional step-up strategy.
Preliminary data for top-down therapy in CD suggest an improve-
ment in the natural history (25). Thus, predictors of aggressive IBD
may be helpful in risk stratification and to decide who will bene-
fit from early aggressive therapy. Improved understanding of the
pathogenesis of IBD as well as biomarker identification will hope-
fully facilitate risk stratification and identification of patients who
will benefit from early top-down treatment (26, 27).
THERAPEUTICS OTHER THAN TNF INHIBITORS
As there is a large unmet need in the therapeutic options for
patients with IBD, targeting molecular pathways other than TNF-α
is a recent approach in the management of IBD (Table 1) (28).
The efficacy of ustekinumab, a monoclonal antibody targeting
the interleukin (IL)-6 family of receptors, namely the p40 sub-
unit of IL-12/IL-23 (29), has been investigated in CD. While the
clinical remission rates in the induction therapy did not differ sig-
nificantly from placebo at week 6, the maintenance therapy with
ustekinumab every 8 weeks resulted in a significantly higher clin-
ical remission at week 22 (42%) as compared with placebo (27%,
p= 0.03) among patients with anti-TNF resistance (30).
Adhesion molecules are also considered important targets
for therapeutic intervention in IBD, and antibodies directed
against cell-adhesion molecules have been developed. They sup-
press inflammation through inhibition of leukocyte adhesion and
transmigration into inflamed tissues. The first approved adhe-
sion inhibitor targeting the α4 integrin (natalizumab) was found
to be effective for both induction and maintenance of CD (31,
32). However, its clinical use was hampered as cases of the
fatal progressive multifocal leukoencephalopathy (PML) caused
by reactivation of JC virus have been reported (33). Nonethe-
less, natalizumab has been approved by the FDA for CD with a
“black box warning” for patients who are refractory to conven-
tional therapy, including TNF inhibitors. However, patients must
be free from concomitant immunosuppressants and screened for
JC virus antibodies before this drug is administered, although
the predictive value of this test for PML has been a matter
of debate (33). Natalizumab-associated PML is caused by non-
selective inhibition of the α4β1 heterodimers, which directs leuko-
cytes not only to intestinal mucosa but also to the central ner-
vous system. Therefore, a “second generation” drug class, which
specifically inhibit intestinal β7 integrins have been developed
(vedolizumab). Although no patients treated with vedolizumab
so far acquired the infection, future occurrences should not
be excluded, especially as few patients developed transient JCV
viremia albeit without clinical or MRI findings (34). Hence, a
FDA advisory panel concluded in December 2013 that the ben-
efits of these new drugs may outweigh the potential risk of the
drug causing PML.
Vedolizumab has been studied in UC and CD (35, 36) and
after 52 weeks of treatment, 45% of patients with UC treated with
vedolizumab were corticosteroid-free compared to 16% in the
placebo arm, and 56% had mucosal healing (20% in the placebo
arm) (35). In CD the effect was somewhat weaker (37 versus 22% in
the placebo arm) (36). The favorable safety profile of vedolizumab
and the stable response and remission rates over 1 year are true
assets for this compound.
Apart from vedolizumab, other anti-β7 antibodies are in the
pipeline including etrolizumab (specific for leukocyte β7 integrin
and E-cadherin) (37) and PF-00547,659 specific for endothelial
MAdCAM-1 (38). The latter mentioned drug has, however, not
been associated with activation of JCV viremia (39).
Small molecules such as tofacitinib, a non-biologic oral
inhibitor of Janus kinases (JAKs) selective for JAK1 and JAK3 (40,
41), hold promise with a tolerable safety profile and in contrast
to the drugs already mentioned it can be taken orally (42). Addi-
tionally, small molecules are less expensive than antibodies. The
JAK signaling pathways are responsible for signal transduction of
various cytokine receptors involved in both the innate and adap-
tive immune compartments of IBD (43, 44). In UC tofacitinib has
been very successful with a clinical response at week 8 of up to
78% compared with 42% in the placebo arm (41). However, this
drug has no efficacy in CD (45).
Nanomedicine is an emerging area using nanotechnology
for medical purposes. It refers to the utilization of molecules
at the nanometer scale, and its potential is to turn molecu-
lar discoveries arising from systems biology into benefit for
patients (46, 47). Nanomedicine allows targeted delivery of drugs
to sites of interest (e.g., inflamed intestine) (48), and may in
this way minimize the required dosing and side-effects (49).
Thus, preclinical investigations with oral TNF-α-targeting siR-
NAs loaded into polyactide nanoparticles capable of localizing
and silencing gene transcripts at sites of intestinal inflamma-
tion are promising (50, 51). Although nanomedicine is still in
the making, the size-dependent accumulation of nanocarriers
at sites of inflamed intestine can be utilized to increase clinical
efficacy, diminish side-effects and open for new delivery routes
for fragile (bio)molecules. Taken together, this novel principle
of therapy has a huge potential for management of IBD in the
future (52).
Head-to-head comparisons of the new agents mentioned with
existing therapies would advance the care of our patients and
enable the best strategy for the individuals to be selected.
CONCLUSION
A number of important discoveries will impact the future of IBD
therapy, and the use of biomarkers and imaging will increase in the
years to come. Pharmacokinetics and therapeutic monitoring will
be used to customize drug dosing for individual patients. Treat-
ment end-points will evolve from symptoms to mucosal healing;
the prevention of structural damage and the prevention of disabil-
ity. Concomitant therapy with thiopurines and TNF inhibitors
will be used more frequently. The continued discovery of novel
therapeutic targets will provide rationale for a rich pipeline of
future therapeutics, which will change clinical practice at centers
treating IBD.
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Due to the discovery of susceptibility genes, novel cell-subsets,
and insights into antigen-processing and cell-signaling, we have
nowadays acquired a much better understanding of the basis of
IBD (10, 17). With the arrival of targeted therapy in the form
of monoclonal antibodies, small molecule inhibitors, and RNA-
interference-based therapy,we will be given the tools to manipulate
specific inflammatory processes. By integrating these technolo-
gies and the expanding number of candidate pathways, several
new medications can be expected to reach clinical trials in the
coming years. This requires a continuous revealing of biologi-
cal mechanisms, drug kinetics, and potential side-effects. Thus, a
close collaboration between clinicians and research laboratories,
other specialties as well as the pharmaceutical industry seems to be
of paramount importance in creating progress in this expanding
field.
Drug development for IBD holds great promise and patients as
well as gastroenterologists can be hopeful for the future.
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